Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Protean BioDiagnostics has developed and commercialized the Oncology MAPS system, a comprehensive precision medicine platform supporting community-based oncologists with advanced molecular diagnostics, liquid biopsy, digital pathology, and AI-driven analytics. The company has demonstrated clinical utility in improving diagnosis accuracy and enabling personalized treatment selection for various cancers. It partners with technology companies to enhance its offerings (e.g., Nucleai for AI pathology) and recently launched CDX-Prostate in partnership with Nanostics to improve prostate cancer risk assessment in the US market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Anthony Magliocco.